Management and Outcomes of Complications Related to BioZorb Use in Breast-Conserving Surgery: A Retrospective Single-Center Case Series Analysis

REFERENCES

1. 1.↵
   1. Blichert-Toft M,
   2. Nielsen M,
   3. Düring M,
   4. et al.

   Long-term results of breast conserving surgery vs. mastectomy for early stage invasive breast cancer: 20-year follow-up of the Danish randomized DBCG-82TM protocol. Acta Oncol. 2008;47(4):672-681. doi: 10.1080/02841860801971439

   OpenUrlCrossRefPubMedWeb of Science
2. 2.↵
   1. Fisher B,
   2. Anderson S,
   3. Bryant J,
   4. et al.

   Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347(16):1233-1241. doi: 10.1056/NEJMoa022152

   OpenUrlCrossRefPubMedWeb of Science
3. 3.↵
   1. Denham JW,
   2. Sillar RW,
   3. Clarke D

   . Boost dosage to the excision site following conservative surgery for breast cancer: it's easy to miss! Clin Oncol (R Coll Radiol). 1991;3(5):257-261. doi: 10.1016/s0936-6555(05)80873-8

   OpenUrlCrossRefPubMed
4. 4.
   1. Sung S,
   2. Lee JH,
   3. Lee JH,
   4. et al.

   Displacement of surgical clips during postoperative radiotherapy in breast cancer patients who received breast-conserving surgery. J Breast Cancer. 2016;19(4):417-422. doi: 10.4048/jbc.2016.19.4.417

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Yang Z,
   2. Chen J,
   3. Hu W,
   4. et al.

   Planning the breast boost: how accurately do surgical clips represent the CT seroma? Radiother Oncol. 2010;97(3):530-534. doi: 10.1016/j.radonc.2010.09.007

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Wiens N,
   2. Torp L,
   3. Wolff B,
   4. et al.

   Effect of BioZorb® surgical marker placement on post-operative radiation boost target volume. J Radiat Oncol. 2018;7(2):175-179. doi: 10.1007/s13566-017-0339-y

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Foster B,
   2. Sindhu K,
   3. Hepel J,
   4. et al.

   Three-dimensional bioabsorbable tissue marker placement is associated with decreased tumor bed volume among patients receiving radiation therapy for breast cancer. Pract Radiat Oncol. 2019;9(2):e134-e141. doi: 10.1016/j.prro.2018.09.005

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Kaufman CS,
   2. Cross MJ,
   3. Barone JL,
   4. et al.

   A three-dimensional bioabsorbable tissue marker for volume replacement and radiation planning: a multicenter study of surgical and patient-reported outcomes for 818 patients with breast cancer. Ann Surg Oncol. 2021;28(5):2529-2542. doi: 10.1245/s10434-020-09271-2

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Cross MJ,
   2. Lebovic GS,
   3. Ross J,
   4. Jones S,
   5. Smith A,
   6. Harms S

   . Impact of a novel bioabsorbable implant on radiation treatment planning for breast cancer. World J Surg. 2017;41(2):464-471. doi: 10.1007/s00268-016-3711-y

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Srour MK,
    2. Chung A

    . Utilization of BioZorb implantable device in breast-conserving surgery. Breast J. 2020;26(5):960-965. doi: 10.1111/tbj.13657

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Ju T,
    2. Tsai J

    . Surgical excision of BioZorb device eroding through the nipple-areolar complex one year postoperatively: a case report. Breast J. 2021;27(3):256-257. doi: 10.1111/tbj.14168

    OpenUrlCrossRefPubMed
12. 12.↵
    FDA Safety Communications. Update: do not use BioZorb marker implantable radiographic marker devices. U.S. Food & Drug Administration. Published October 25, 2024. Accessed January 23, 2026. fda.gov/medical-devices/safety-communications/update-do-not-use-biozorb-marker-implantable-radiographic-marker-devices-fda-safety-communication